Mereo BioPharma Group plc - MREO
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | Northpond Ventures, LP | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Northpond Ventures GP, LLC | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Northpond Ventures II, LP | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Northpond Ventures II GP, LLC | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | NPV Listed, LLC | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Northpond Ventures, LLC | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Michael P. Rubin | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | JANUS HENDERSON GROUP PLC | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences Public Fund, L.P. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLSP, L.P. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLSP, L.L.C. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences X, L.P. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS X, L.P. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS X, L.L.C. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences XI, L.P. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XI, L.P. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XI, L.L.C. | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | James N. Topper | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Patrick J. Heron | 0.0% | 0 | View |
| Jan 09, 2026 | SCHEDULE 13G | EcoR1 Capital, LLC | 9.4% | 74,500,000 | View |
| Jan 09, 2026 | SCHEDULE 13G | Oleg Nodelman | 9.4% | 74,500,000 | View |
| Jan 09, 2026 | SCHEDULE 13G | EcoR1 Capital Fund Qualified, L.P. | 8.8% | 69,802,840 | View |
| Jan 06, 2026 | SCHEDULE 13G | 683 Capital Management, LLC | 8.18% | 65,083,815 | View |
| Jan 06, 2026 | SCHEDULE 13G | 683 Capital Partners, LP | 8.18% | 65,083,815 | View |
| Jan 06, 2026 | SCHEDULE 13G | Ari Zweiman | 8.18% | 65,083,815 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Mangrove Partners IM, LLC | 4.9% | 38,952,900 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Nathaniel August | 4.9% | 38,952,900 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | JANUS HENDERSON GROUP PLC | 10.2% | 16,290,130 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Janus Henderson Biotech Innovation Master Fund Ltd | 8.7% | 13,759,885 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.